Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Insmed Inc. | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Insmed Inc.

Nicholas A. LaBella Jr., MS, RPh, has joined Insmed as chief scientific officer, a newly-created position on the executive team.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Nicholas A. LaBella Jr., MS, RPh, has joined Insmed as chief scientific officer, a newly-created position on the executive team. Mr. LaBella will oversee the scientific and regulatory analysis related to the company’s ongoing strategic review. He reports to Dr. Melvin Sharoky, Insmed’s chairman.

Mr. LaBella has approximately 30 years of pharmaceutical industry experience, including drug development, clinical operations and regulatory affairs. Most recently, he served as vice president of development and regulatory affairs at Cardiokine, Inc., a privately-held specialty pharmaceutical company.

“Nick’s extensive track record in drug development, clinical operations and regulatory affairs should significantly benefit our strategic review process,” said Dr. Melvin Sharoky, Insmed’s chairman. “Nick recently served as a scientific consultant to Insmed and his counsel has been instrumental in our scientific evaluations.As we continue our review of late-stage development assets, adding Nick to the internal management team should further streamline the review process and add greater efficiency to the scientific and regulatory analysis of each asset.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics